AngioDynamics Presents New VenaCure Procedure Kit.

QUEENSBURY, N.Y. -- AngioDynamics, Inc., (Nasdaq:ANGO) today announced its plans to present the Company's new VenaCure(TM) laser vein treatment procedure kit at the American College of Phlebology's 18th Annual Congress at Marco Island, Fla., November 4-7, 2004. The Company expects to ship kits within the United States mid-November.

VenaCure laser vein treatment is a minimally invasive alternative for the treatment of severe varicose veins. The procedure lasts about 45 minutes and offers patients an effective out-patient alternative to surgical ligation and vein stripping.

AngioDynamics' new VenaCure procedure kit is designed to be used with its Precision 980(TM) laser as well as other diode lasers with an SMA 905 connector. The kit was developed to help improve patient safety while providing ease of use for physicians.

Highlights of the kit include, but are not limited to:

--separately packaged sterile micro access kit - designed for less waste;

--double-ended, straight and J-tipped .035" guidewire - allows for physician preference;

--quality manufactured fiber with our patent pending Sheath-Lok(TM) system - designed for precise placement and accurate performance

A brand new addition to the kit is the patent pending 4F Tre-Sheath(TM) Introducer, one of the lowest profile sheaths on the market for this procedure. The Tre-Sheath features a translucent, super-echogenic braided shaft, with centimeter markers throughout the length of the sheath and at the tip. These features are intended to heighten visibility at different stages during the procedure. This product is also offered in a variety of lengths. These specific features and patent pending design were developed to provide the physician with a more user-friendly approach to this minimally invasive procedure.

Commenting for AngioDynamics, Product Manager David Doster said, "AngioDynamics' design team has been working with leading physicians in the industry on this newly designed sheath and kit. It is very rewarding to see our commitment to the constant improvement of the laser vein treatment, both for patients and physicians, come to fruition. We believe this new procedure kit -- featuring the Tre-Sheath Introducer -- is a prime example of AngioDynamics' leadership commitment to this new procedure."

For additional information on the VenaCure laser vein treatment and the new procedure kit, contact David Doster at 1-800-772-6446, ext. 126, Email: [e-mail]. You may also visit either the laser treatment web site at www.venacure.com or the AngioDynamics web site at www.angiodynamics.com.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) designs, develops, manufactures and markets innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease. It offers a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. AngioDynamics' diversified product line includes angiographic catheters, hemodialysis catheters, PTA dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, as well as drainage products. AngioDynamics is a majority-owned subsidiary of E-Z-EM, Inc. (AMEX:EZM), a leading manufacturer of contrast agents for gastrointestinal radiology.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", "believes", "seeks", "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the VenaCure(TM) Laser Vein Treatment System and the new procedure kit, results of the pending patent litigation with Diomed, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics Inc., including but not limited to its Form 10K for the year ended May 29, 2004, may affect the actual results achieved by the Company.